Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Crescent Biopharma, Inc.NASDAQ: CBIO

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $25.77M rose 81.2% year over year, behind the +230.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 74.8% from the prior quarter. Over 3 fiscal years it compounded at +51.0% a year.

Context

  • Operating expenses amounted to 1507.5% of revenue in FY2025.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +81.2% toward the trailing-twelve-month pace of +230.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.77M-74.8% QoQ
Last fiscal yearDec 2025
$163.48M+227.6% YoY
LTMMar 2026
$175.02M+230.2% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+81.2%——
1 year+227.6%——
3-year CAGR+51.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
163.48M USD
Year-over-year change
+227.6%
4-year CAGR
+26.1%

Operating Expenses vs competitors

How CBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +230.2% is the 2nd highest of 10, against a peer median of -0.7%.
  • Operating expenses amounts to 1472.9% of revenue for CBIO, versus a peer median of 195.8%.
CBIO Competitors
Operating Expenses for CBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$596M USD-0.7%+16.7%509.4%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$333.75M USD+278.1%+101.5%297994.6%
ZYMEZymeworks Inc.LTM Sep 2026$217.29M USD+5.9%-11.0%81.7%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$175.02M USD+230.2%+51.0%1472.9%
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M USD-10.6%-12.1%110.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$99.95M USD-10.4%-13.9%281.2%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$74.43M USD+18.8%+19.7%—
CNTXContext Therapeutics Inc.LTM Mar 2026$43.51M USD+37.6%+37.2%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥34.74M CNY-93.5%-66.4%—
CGENCompugen Ltd.LTM Mar 2026$33.28M USD-2.6%-8.4%45.8%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CBIO) —-0.7%-8.4%195.8%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.16M75K10K010.84M
Cost of Revenue00000
Gross Profit1.16M75K10K010.84M
Gross Margin100.0%100.0%100.0%—100.0%
Research & Development47.49M28.39M20.07M28.06M138.09M
Selling, General & Admin17.12M19.09M19.21M16.32M25.39M
Operating Expenses64.61M47.48M39.29M49.9M163.48M
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
EBITDA(63.18M)(47.2M)(39.12M)(44.17M)(149.67M)
EBITDA Margin-5447.9%-62927.6%-391213.5%—-1380.2%
Operating Income(63.45M)(47.4M)(39.28M)(49.9M)(152.63M)
Operating Margin-5470.7%-63204.4%-392752.9%—-1407.5%
Interest Income19.77K714.52K2.38M1M2.88M
Interest Expense000852K2.19M
Other Income / Expenses19.77K714.96K2.38M1.37M690K
Income Before Tax(63.43M)(46.69M)(36.9M)(48.52M)(151.94M)
Pre-Tax Margin-5469.0%-62251.1%-368987.8%—-1401.2%
Income Tax Expense00002M
Net Income(63.43M)(46.69M)(36.9M)(48.52M)(153.94M)
Net Margin-5469.0%-62251.7%-368994.2%—-1419.6%
EPS (Basic)(1.23)(0.89)(0.58)(1.40)(14.78)
EPS (Diluted)(1.23)(0.89)(0.58)(1.40)(14.78)
Weighted Avg Shares51.45M52.53M63.34M19.5M10.41M
Weighted Avg Shares (Diluted)51.45M52.53M63.34M19.5M10.41M

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.